Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

被引：3
|
作者：
Gumus, Mahmut
Chen, Chieh-I
Ivanescu, Cristina
Kilickap, Saadettin
Bondarenko, Igor
Ozguroglu, Mustafa
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Harnett, James
Mastey, Vera
Naumann, Ulrike
Reaney, Matthew
Konidaris, Gerasimos
Sasane, Medha
Brady, Keri
Li, Siyu
Gullo, Giuseppe
Rietschel, Petra
Sezer, Ahmet
机构：
[1] Istanbul Medeniyet Univ, Istanbul, Turkey
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] IQVIA, Durham, NC USA
[4] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey
[5] Dnipropetrovsk State Med Acad, City Multifield Clin Hosp, Dnepropetrovsk, Ukraine
[6] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[7] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia
[8] Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey
[9] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[10] Sanofi, Reading, Berks, England
[11] Sanofi, Bridgewater, NJ USA
[12] Sanofi, Cambridge, MA USA
[13] Baskent Univ, Dept Med Oncol, Adana, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9078
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [2] Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Ozguroglu, M.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Fuang, H. G.
    Kulyaba, Y.
    Zyuhal, K.
    Scheusan, R. I.
    Baramidze, A.
    Garassino, M. C.
    Li, Y.
    Jia, X.
    Kaul, M.
    Perez, J.
    Seebach, F.
    Lowy, I.
    Pouliot, J. F.
    Kim, E.
    Rietschel, P.
    Magnan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S35 - S35
  • [3] Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S125 - S126
  • [4] "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study"(vol 129, pg 118, 2023)
    Gumus, M.
    Chen, C-, I
    Ivanescu, C.
    CANCER, 2024, 130 (09) : 1715 - 1715
  • [5] EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%
    Rizvi, N.
    Lee, S.
    Curtis, P.
    Caldwell, W.
    Gao, B.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S932
  • [6] Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
    Bondarenko, I.
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Mcginniss, J.
    Pouliot, J.
    Lee, S.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S951 - S951
  • [7] EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
    Rizvi, N.
    Lee, S.
    Curtis, P.
    Caldwell, W.
    Gao, B.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S931
  • [8] Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
    Ozguroglu, Mustafa
    Sezer, Ahmet
    Kilickap, Saadettin
    Gumus, Mahmut
    Bondarenko, Igor
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Bentsion, Dmitry
    Gladkov, Oleg
    Clingan, Philip R.
    Sriuranpong, Virote
    Rizvi, Naiyer A.
    McGinniss, Jennifer
    Pouliot, Jean-Francois
    Lee, Sue
    Seebach, Frank A.
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
  • [10] Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation
    Bondarenko, I.
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    ANNALS OF ONCOLOGY, 2022, 33 : S84 - S85
12345